CPRX•benzinga•
B of A Securities Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga